<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2021.03.09.21253206</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Genetic and Genomic Medicine</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5748-6652</contrib-id>
<name><surname>Palmos</surname><given-names>Alish B.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
<xref ref-type="author-notes" rid="n1">&#x2020;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Millischer</surname><given-names>Vincent</given-names></name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="author-notes" rid="n1">&#x2020;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Menon</surname><given-names>David K.</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nicholson</surname><given-names>Timothy R.</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a9">10</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Taams</surname><given-names>Leonie</given-names></name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Michael</surname><given-names>Benedict</given-names></name>
<xref ref-type="aff" rid="a7">8</xref>
</contrib>
<contrib contrib-type="author">
<collab>COVID Clinical Neuroscience Study Consortium</collab>
</contrib>
<contrib contrib-type="author">
<name><surname>H&#x00FC;bel</surname><given-names>Christopher</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a8">9</xref>
<xref ref-type="author-notes" rid="n2">&#x2021;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Breen</surname><given-names>Gerome</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n2">&#x2021;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Social, Genetic &#x0026; Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &#x0026; Neuroscience, King&#x2019;s College London</institution>, <country>UK</country></aff>
<aff id="a2"><label>2</label><institution>UK National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health, South London and Maudsley Hospital</institution>, London, <country>UK</country></aff>
<aff id="a3"><label>3</label><institution>Department of Psychiatry and Psychotherapy, Medical University of Vienna</institution>, Vienna, <country>Austria</country></aff>
<aff id="a4"><label>4</label><institution>Department of Molecular Medicine and Surgery, Karolinska Institutet</institution>, Stockholm, <country>Sweden</country></aff>
<aff id="a5"><label>5</label><institution>Division of Anaesthesia, Department of Medicine, University of Cambridge</institution></aff>
<aff id="a6"><label>6</label><institution>Centre for Inflammation Biology &#x0026; Cancer Immunology, Department of Inflammation Biology, School of Immunology &#x0026; Microbial Sciences, King&#x2019;s College London</institution>, <country>UK</country></aff>
<aff id="a7"><label>8</label><institution>Institute of Infection and Global Health, University of Liverpool</institution>, <country>UK</country></aff>
<aff id="a8"><label>9</label><institution>National Centre for Register-based Research, Department of Economics and Business Economics, Aarhus University</institution>, Aarhus, <country>Denmark</country></aff>
<aff id="a9"><label>10</label><institution>Institute of Psychiatry, Psychology &#x0026; Neuroscience, King&#x2019;s College London</institution>, <country>UK</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Indicates corresponding author (<email>alish.palmos@kcl.ac.uk</email>)</corresp>
<fn id="n1"><label>&#x2020;</label><p>Indicates joint first authorship</p></fn>
<fn id="n2"><label>&#x2021;</label><p>Indicates joint last authorship</p></fn>
</author-notes>
<pub-date pub-type="epub">
<year>2021</year>
</pub-date>
<elocation-id>2021.03.09.21253206</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>3</month>
<year>2021</year>
</date>
<date date-type="rev-recd">
<day>09</day>
<month>3</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>3</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2021</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="21253206.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>The COVID-19 pandemic death toll now surpasses two million individuals and there is a need for early identification of individuals at increased risk of mortality. Host genetic variation partially drives the immune and biochemical responses to COVID-19 that lead to risk of mortality. We identify and prioritise blood proteins and biomarkers that may indicate increased risk for severe COVID-19, via a proteome Mendelian randomization approach by collecting genome-wide association study (GWAS) summary statistics for &#x003E;4,000 blood proteins. After multiple testing correction, troponin I3, cardiac type (TNNI3) had the strongest effect (odds ratio (O.R.) of 6.86 per standard deviation increase in protein level), with proteinase 3 (PRTN3) (O.R.=2.48), major histocompatibility complex, class II, DQ alpha 2 (HLA-DQA2) (O.R.=2.29), the C4A-C4B heterodimer (O.R.=1.76) and low-density lipoprotein receptor-related protein associated protein 1 (LRPAP1) (O.R.=1.73) also being associated with higher odds of severe COVID-19. Conversely, major histocompatibility complex class I polypeptide-related sequence A (MHC1A) (O.R.=0.6) and natural cytotoxicity triggering receptor 3 (NCR3) (O.R.=0.46) were associated with lower odds. These proteins are involved in heart muscle contraction, natural killer and antigen presenting cells, and the major histocompatibility complex. Based on these findings, it may be possible to better predict which patients may develop severe COVID-19 and to design better treatments targeting the implicated mechanisms.</p>
</abstract>
<counts>
<page-count count="26"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>COVID-19 Clinical Neuroscience Study is funded by the Medical Research Council.</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>IRB/oversight body is exempted.
</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in late 2019 in Wuhan, China, as the cause of what is now termed the coronavirus disease 2019 (COVID-19) that rapidly evolved into a global pandemic (<xref ref-type="bibr" rid="c1">1</xref>,<xref ref-type="bibr" rid="c2">2</xref>). As of February 2021, more than 100 million cases have been confirmed worldwide with total deaths exceeding 2 million (<xref ref-type="bibr" rid="c3">3</xref>). COVID-19 pathology encompasses a wide spectrum of clinical manifestations from asymptomatic, over mild, moderate, to severe infections (around 15&#x0025;) (<xref ref-type="bibr" rid="c1">1</xref>,<xref ref-type="bibr" rid="c2">2</xref>). Severe COVID-19 commonly requires hospitalization and intensive care with assisted respiratory support, and subsequent respiratory failure is the most common reason for COVID-19 associated mortality (<xref ref-type="bibr" rid="c4">4</xref>).</p>
<p>A dysregulated pro- and anti-inflammatory immunomodulatory response drives much of the severe pathophysiology of COVID-19 and comprises alveolar damage, lung inflammation and pathology of an acute respiratory distress syndrome (<xref ref-type="bibr" rid="c1">1</xref>,<xref ref-type="bibr" rid="c2">2</xref>)<sup>,(<xref ref-type="bibr" rid="c5">5</xref>,<xref ref-type="bibr" rid="c6">6</xref>)</sup>. While initial descriptions and a response to corticosteroids led to a label of a &#x201C;cytokine storm&#x201D; (<xref ref-type="bibr" rid="c7">7</xref>) in severe disease cases, recent reports suggest that the abnormalities in host response may be more complex and nuanced (<xref ref-type="bibr" rid="c8">8</xref>). Given that the innate immune response has an individual-level genetic basis, genetic variants carried by an individual could play an important role in the individual-level immune response and, therefore, may influence progression and severity of COVID-19. Most biological systems are based on the interaction of biological and environmental factors. The influence of environmental factors can confound measured associations between biological markers and diseases outcomes. Therefore, studying immunomodulatory blood proteins in COVID-19 patients is difficult due to potential confounding effects of factors, such as initial viral exposure/inoculum, smoking behaviour and high body mass index (BMI). These factors themselves are associated with increased pro-inflammatory cytokine levels and may represent independent risk factors for severe COVID-19 (<xref ref-type="bibr" rid="c9">9</xref>&#x2013;<xref ref-type="bibr" rid="c11">11</xref>).</p>
<p>Numerous genome-wide association studies (GWASs) in healthy populations associated genetic variants with immunomodulatory blood proteins (<xref ref-type="bibr" rid="c12">12</xref>&#x2013;<xref ref-type="bibr" rid="c14">14</xref>). In addition, the COVID-19 Host Genetics Initiative carried out GWASs on COVID-19 subtypes to understand the role of host genetic factors in susceptibility and severity of COVID-19 (<xref ref-type="bibr" rid="c15">15</xref>). These data represent a powerful source of information to find new biomarkers and therapeutic leads. The method of Mendelian randomization can be applied to investigate the relationship between immunomodulatory blood proteins and severe COVID-19 infection. This exploits the fact that alleles are randomly inherited from parent to offspring in a manner analogous to a randomised-controlled trial, and allows estimation of putative causal effects of an exposure on a disease while avoiding confounding environmental effects, thus overcoming some of the limitations of observational studies. Recent advancements in Mendelian randomization methods allow use of GWAS summary statistics data, to identify genetic proxies (i.e., instrumental variables) of modifiable risk factors and testing their association with disease outcomes (<xref ref-type="bibr" rid="c16">16</xref>). We, therefore, conducted Mendelian randomization analyses between the levels of a large number of blood proteins and severe COVID-19 to identify putative causal associations that could be prioritised in clinical studies.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<sec id="s2a">
<title>Blood protein GWAS data</title>
<p>In total, we amassed 5,305 sets of GWAS summary statistics for blood biomarkers (<xref ref-type="bibr" rid="c12">12</xref>,<xref ref-type="bibr" rid="c13">13</xref>,<xref ref-type="bibr" rid="c84">84</xref>&#x2013;<xref ref-type="bibr" rid="c89">89</xref>). A systematic search was performed based on the ontology lookup service (OLS; <ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/ols/index">www.ebi.ac.uk/ols/index</ext-link>) using R and the packages &#x2018;rols&#x2019; and &#x2018;gwasrapid&#x2019; between July 7th and July 27th, 2020. OLS is a repository for biomedical ontologies, such as gene ontology (GO) or the experimental factor ontology (EFO), including a systematic description of many experimental variables. First, all subnodes of the EFO &#x2018;protein measurements&#x2019; (EFO:0004747) were determined using an iterative process based on the package &#x2018;rols&#x2019;. Overall, 628 unique EFO IDs were determined. Subsequently, all genetic associations reported in the GWAS Catalog (<xref ref-type="bibr" rid="c90">90</xref>) (<ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/gwas/">www.ebi.ac.uk/gwas/</ext-link>) were determined and linked to the corresponding study using the package &#x2018;gwasrapid&#x2019;. One hundred and seventy-eight unique GWAS catalog accession IDs with available summary statistics were curated manually before inclusion. In order to expand the dataset, studies published at a later date were included manually and the first and the last author of studies without publicly available summary statistics were contacted.</p>
<p>In total, we included eight publications for which summary data was readily available and processed those using standard GWAS summary statistics quality control metrics including removal of incomplete genetic variants, variants with information metrics of lower than 0.6 and allele frequencies more extreme than 0.005 or 0.995. Allele frequencies were taken from the 1,000 Genomes Project data where needed (<xref ref-type="bibr" rid="c91">91</xref>). See Supplementary Table 1 for a full list of the studies included in these analyses.</p>
</sec>
<sec id="s2b">
<title>COVID-19 GWAS data</title>
<p>We downloaded the COVID-19 Host Genome Initiative GWAS meta-analysis (<xref ref-type="bibr" rid="c15">15</xref>) of &#x201C;very severe respiratory confirmed covid vs not hospitalized covid&#x201D; (release 4, October 2020; <ext-link ext-link-type="uri" xlink:href="http://www.covid19hg.org/results/">www.covid19hg.org/results/</ext-link>). Cases and controls were defined as SARS-CoV-2 infected individuals within a clinical window of 15-90 days from diagnosis; with cases defined as mortality or the need for respiratory support (intubation, continuous positive airway pressure or bilevel positive airway pressure) and controls defined as surviving individuals who did not require respiratory support at any point since diagnosis.(<xref ref-type="bibr" rid="c15">15</xref>) The European sample consisted of 269 cases and 688 controls.</p>
<p>This GWAS was selected due to its extreme phenotyping, focusing specifically on mortality and respiratory failure (cases) compared to discharge from hospital without respiratory complications (controls). Subsequent COVID-19 GWAS are based on different, much less severe outcomes and broader phenotypes such as hospitalisation versus non hospitalisation that do not directly address the encompassing genetic basis for COVID-19 mortality or respiratory failure.</p>
</sec>
<sec id="s2c">
<title>Mendelian randomization</title>
<p>To examine the influence of blood proteins on the risk of developing severe COVID-19, we selected genetic variants, predominantly single nucleotide polymorphisms (SNPs), that were strongly associated with actual blood protein levels in 3,609 genome-wide analyses of single proteins using robust methodologies (see supplement for more details on how the proteins were measured). Using these genetic loci as proxies for protein levels we performed an analysis using Mendelian randomization, a method that enables tests of putative causal associations of these blood proteins with the development of severe COVID-19. We used the Generalised Summary-based Mendelian randomization (GSMR) method as the base method (<xref ref-type="bibr" rid="c92">92</xref>).</p>
<p>For all GWASs, SNPs were used as instrumental variables and were selected by applying a suggestive <italic>p-value</italic> threshold (<italic>p</italic> &#x003C; 5 &#x00D7; 10<sup>&#x2212;6</sup>), in order to identify enough SNPs in common between the exposure (i.e., blood marker) and outcome (i.e. severe COVID-19). Where possible (due to SNPs in common between the exposure and the outcome), bidirectional analyses were performed between 3,609 blood markers and severe COVID-19, resulting in a total of 7,406 tests. To account for multiple testing, we calculated false discovery rate (FDR) corrected <italic>Q</italic> values using the p.adjust function in R (<italic>p</italic><sub>FDR</sub> = 0.1).(<xref ref-type="bibr" rid="c93">93</xref>)</p>
</sec>
<sec id="s2d">
<title>Sensitivity analyses</title>
<p>To test for robustness, we performed sensitivity analyses on our significant results from the GSMR analyses using additional Mendelian randomization methods, including the weighted median (WM), inverse variance-weighted (IVW), robust adjusted profile score (MR-RAPS), and MR-Egger methods (<xref ref-type="bibr" rid="c94">94</xref>&#x2013;<xref ref-type="bibr" rid="c96">96</xref>). In order to pass our sensitivity analyses, at least three of these four methods must agree with the GSMR results.</p>
</sec>
<sec id="s2e">
<title>Clinical application</title>
<p>The protein with the highest effect size was investigated for its clinical application. For this we used the Open Targets Platform (<xref ref-type="bibr" rid="c20">20</xref>). Specifically we focus on gene ontology and drug targets.</p>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<p>Out of the possible 7,406 associations tested, we tested 3,609 associations with severe COVID-19 as the exposure and 3,797 associations with severe COVID-19 as the outcome. No tests with severe COVID-19 as the exposure reached a level of statistical significance and are therefore not reported. See <xref rid="tbl1" ref-type="table">Table 1</xref> for significantly associated blood markers alongside test statistics.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><title>Mendelian randomization results</title>
<p>This table details significant, false discovery rate-(FDR)-corrected Mendelian randomization results, using the Generalised Summary Data-based Mendelian randomization (GSMR) method. Seven blood markers were associated with a significantly increased risk for severe COVID-19 while two blood markers were associated with a significantly decreased risk for severe COVID-19. CREB3L4 and DEFB119 did not survive our sensitivity analyses. The genetic instruments for C4a-C4b and HLA-DQA2 were in low to moderate linkage disequilibrium but this did not influence results (see Supplementary Table 4). The table presents the log odds statistics and corresponding standard error as well as odds ratios, 95&#x0025; confidence intervals, and the FDR-adjusted Q values (p<sub>FDR</sub> = 0.1).</p></caption>
<graphic xlink:href="21253206v1_tbl1.tif"/>
</table-wrap>
<sec id="s3a">
<title>Elevated risk for severe COVID-19</title>
<p>After multiple testing correction (<italic>p</italic><sub>FDR</sub> = 0.1), seven blood markers were associated with a statistically significantly elevated risk of severe COVID-19 (see <xref rid="fig1" ref-type="fig">Figure 1</xref>). One standard deviation (SD) increase in troponin I, cardiac muscle (TNNI3) was associated with 589&#x0025; (95&#x0025; CI: 5.91-7.80, <italic>q</italic> = 0.06) higher odds of severe COVID-19. One SD increase in myeloblastin (PRTN3) was associated with 148&#x0025; (95&#x0025; CI: 2.04-2.91, <italic>q</italic> = 0.04) higher odds of severe COVID-19. One SD increase in major histocompatibility complex (MHC), class II, DQ alpha 2 (HLA-DQA2) was associated with 129&#x0025; (95&#x0025; CI: 1.94-2.64, <italic>q</italic> = 0.01) higher odds of severe COVID-19. One SD increase in complement components 4A and 4B (C4a-C4b) was associated with 76&#x0025; (95&#x0025; CI: 1.51-2.01, <italic>q</italic> = 0.02) higher odds of severe COVID-19. One SD increase in low-density lipoprotein (LDL) receptor-related protein associated protein 1 (LRPAP1) was associated with 73&#x0025; (95&#x0025; CI: 1.49-1.97, <italic>q</italic> = 0.02) higher odds of severe COVID-19 infection.</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Blood markers putatively causally associated with severe COVID-19</title>
<p>Summary figure of the false discovery rate-corrected (p<sub>FDR</sub> = 0.1) Mendelian randomization results using the Generalised Summary data-based Mendelian randomization (GSMR) method. Odds ratios (ORs) of the blood markers associated with severe COVID-19 are displayed on the x-axis (with 95&#x0025; confidence intervals). The blood markers are displayed on the y-axis. The dashed red line represents an odds ratio of one (i.e., no effect). Seven blood markers were associated with a significantly increased risk for severe COVID-19 and two blood markers were associated with a significantly decreased risk for severe COVID-19 (q<sub>FDR</sub> &#x2264; 0.1). Markers which additionally survived our sensitivity analyses are marked with an asterisk (&#x002A;). C4A = complement C4A (Rodgers blood group), C4B = complement C4B (Chido blood group), CREB3L4 = cAMP responsive element binding protein 3 like 4, DEFB119 = beta-defensin 119, HLA-DQA2 = major histocompatibility complex (MHC), class II, DQ alpha 2, LRPAP1 = low-density lipoprotein (LDL) receptor-related protein associated protein 1, MICA = MHC class I polypeptide-related sequence A, NCR3 = natural cytotoxicity triggering receptor 3, PRTN3 = proteinase 3, TNNI3 = troponin I3, cardiac type.</p></caption>
<graphic xlink:href="21253206v1_fig1.tif"/>
</fig>
</sec>
<sec id="s3b">
<title>Decreased risk for severe COVID-19</title>
<p>A one SD increase in MHC class I polypeptide-related sequence A (MICA) was associated with 40&#x0025; (95&#x0025; CI: 0.41-0.78, <italic>q</italic> = 0.001) lower odds and one SD increase in natural cytotoxicity triggering receptor 3 (NCR3) was associated with 54&#x0025; (95&#x0025; CI: 0.06-0.86, <italic>q</italic> = 0.09) lower odds of severe COVID-19 (see <xref rid="fig1" ref-type="fig">Figure 1</xref>).</p>
</sec>
<sec id="s3c">
<title>Sensitivity analyses</title>
<p>To further increase confidence in the findings, we additionally filtered our results for those concurrent with results calculated by additional Mendelian randomization methods (WM, IVW and MR-RAPS). Our sensitivity analyses revealed that the TNNI3, PRTN3, HLA-DQA2, C4A-C4B, LRPAP1, MICA and NCR3 associations with severe COVID-19 were confirmed. The two additional markers, cAMP responsive element binding protein 3 like 4 (CREB3L4) and beta-defensin 119 (DEFB119), associated with an increased risk for severe COVID-19 with the GSMR method, did not survive our sensitivity analyses. See <xref rid="fig2" ref-type="fig">Figure 2</xref> for Mendelian randomization scatter plots of the sensitivity analyses and Supplementary Table 2 for a full results table of the sensitivity analyses.</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Sensitivity analyses for blood markers putatively causally associated with severe COVID-19</title>
<p>Mendelian randomization scatter plots using the inverse variance weighted, robust adjusted profile score, MR-Egger and weighted median methods associating each blood marker with severe COVID-19. Single nucleotide polymorphism (SNP) effects of the blood markers (i.e., exposures) are displayed on the x-axis and SNP effects of severe COVID-19 (outcome) are displayed on the y-axis. The horizontal line of each point represents the standard error of the SNP-exposure association and the vertical line the standard error of the SNP-outcome association. The effect of (A) TNNI3; (B) PRTN3; (C) HLA-DQ2; (D) DEFB119; (E) CREB3L4; (F) C4a-C4b; (G) LRPAP1; (H) MICA; (I) NCR3. SNP = single nucleotide polymorphism; C4A = complement C4A (Rodgers blood group), C4B = complement C4B (Chido blood group), CREB3L4 = cAMP responsive element binding protein 3 like 4, DEFB119 = beta-defensin 119, HLA-DQA2 = major histocompatibility complex (MHC), class II, DQ alpha 2, LRPAP1 = low-density lipoprotein (LDL) receptor-related protein associated protein 1, MICA = MHC class I polypeptide-related sequence A, NCR3 = natural cytotoxicity triggering receptor 3, PRTN3 = proteinase 3, TNNI3 = troponin I3, cardiac type.</p></caption>
<graphic xlink:href="21253206v1_fig2.tif"/>
</fig>
<p>Several of the proteins (MHC1A, NC3R, C4a-C4b, and HLA-DQA2) are encoded by non-overlapping genes in separate locations within the MHC (major histocompatibility complex) region, located on chromosome 6 (<xref ref-type="bibr" rid="c17">17</xref>&#x2013;<xref ref-type="bibr" rid="c19">19</xref>). We verified that the associations observed are independent and not driven by linkage disequilibrium between the genetic instrumental variables used (see Supplementary Table 3). HLA proteins are vital in evoking immune responses to antigenic stimuli thereby orchestrating cellular and humoral immunity. These molecules facilitate the recognition of self or altered-self vs. non-self proteins by the body&#x2019;s immune system (<xref ref-type="bibr" rid="c17">17</xref>&#x2013;<xref ref-type="bibr" rid="c19">19</xref>).</p>
</sec>
<sec id="s3d">
<title>Clinical application</title>
<p>Due to its large effect, TNNI3 was further investigated for potential clinical application using the Open Targets Platform (<xref ref-type="bibr" rid="c20">20</xref>). We highlight the upstream effect that TNNI3 may be having on heart muscle contraction, which may be having a negative downstream effect on a wide range of biological processes in the nervous, respiratory and digestive systems (see Supplementary Figure 1 for a bubble plot of genetically associated processes with TNNI3). In addition, we identify levosimendan, a positive inotropic agent having ATP-dependent potassium-channel-opening and calcium-sensitizing effects by binding to a calcium sensing myocardial complex consisting of cardiac troponin C and troponin I(<xref ref-type="bibr" rid="c20">20</xref>)<sup>,(<xref ref-type="bibr" rid="c21">21</xref>,<xref ref-type="bibr" rid="c22">22</xref>)</sup>. This is a clinically approved drug used for heart failure, kidney failure and SARS (<ext-link ext-link-type="uri" xlink:href="https://www.targetvalidation.org/summary?drug=CHEMBL2051955">https://www.targetvalidation.org/summary?drug=CHEMBL2051955</ext-link>). We highlight the potential role levosimendan for severe COVID-19 (see Supplementary Figure 2 for a bubble plot of druggable targets associated with TNNI3 and levosimendan), but emphasise the need for further exploration of this relationship.</p>
</sec>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>Our proteome-wide analysis of the influence of the blood levels of 3,609 proteins on risk for severe COVID-19 using Mendelian randomization, yielded evidence consistent with higher blood levels of TNNI3, PRTN3, HLADQA2, C4a-C4b and LRPAP1 being putative causal risk factors for severe COVID-19, and higher blood levels of MHC1A and NCR3 being protective against severe COVID-19. All of these proteins have detectable blood plasma or serum levels; we summarised functions of these blood markers in Supplementary Table 4. It is important to note that we did not identify the typical canonical immune proteins (such as interleukin-6 or C-reactive protein)(<xref ref-type="bibr" rid="c23">23</xref>,<xref ref-type="bibr" rid="c24">24</xref>), suggesting that with a larger database we may be able to pinpoint proteins that are upstream of major inflammatory mechanisms.</p>
<p>TNNI3, which codes for cardiac troponin I, showed the largest effect on COVID-19 severity in our Mendelian randomization analysis (OR per SD increase in TNNI3 level = 6.86, 95&#x0025; C.I. 5.91-7.80). Cardiac troponin I is highly specific for heart muscle and higher concentrations in the blood are associated with higher general in-hospital mortality for a number of illnesses (<xref ref-type="bibr" rid="c25">25</xref>). It serves as a sensor of intracellular calcium, regulating the interaction between thick and thin sarcomere filaments during the heart muscle contraction (<xref ref-type="bibr" rid="c26">26</xref>). We hypothesise that this protein may be relevant to COVID-19 as &#x223C;40&#x0025; of deaths in a cohort from Wuhan (<xref ref-type="bibr" rid="c27">27</xref>) were attributed to myocardial damage and heart failure, as well as increased mortality in individuals with both COVID-19 and acute cardiac injury (<xref ref-type="bibr" rid="c28">28</xref>). Between 12-28&#x0025; of patients with COVID-19 present with elevated troponin (<xref ref-type="bibr" rid="c29">29</xref>&#x2013;<xref ref-type="bibr" rid="c32">32</xref>) are more likely to require intensive care (<xref ref-type="bibr" rid="c29">29</xref>,<xref ref-type="bibr" rid="c33">33</xref>), have higher in-hospital mortality(<xref ref-type="bibr" rid="c28">28</xref>,<xref ref-type="bibr" rid="c30">30</xref>,<xref ref-type="bibr" rid="c32">32</xref>,<xref ref-type="bibr" rid="c34">34</xref>&#x2013;<xref ref-type="bibr" rid="c36">36</xref>) and show myocardial injury after recovery (<xref ref-type="bibr" rid="c37">37</xref>). Different cardiovascular complications, including myocarditis,(<xref ref-type="bibr" rid="c38">38</xref>) microangiopathy, myocardial infarction, or a dysregulated host immune response have been proposed to explain the high mortality in COVID-19(<xref ref-type="bibr" rid="c39">39</xref>) and troponin may be a predictor for mortality independent of inflammation.(<xref ref-type="bibr" rid="c40">40</xref>) In addition, TNNI3 has been associated with angiotensin-converting enzyme 2 (ACE2) upregulation in obstructive hypertrophic cardiomyopathy(<xref ref-type="bibr" rid="c41">41</xref>) and is shown to be a related target of ACE2(<xref ref-type="bibr" rid="c20">20</xref>). Given the importance of ACE2 in COVID-19,(<xref ref-type="bibr" rid="c42">42</xref>) this further implicates TNNI3 as an important target of severe disease pathophysiology (see Supplementary Table 5 for TNNI3 associated proteins). Levosimendan has been shown to exert action on the myocardial troponin complex,(<xref ref-type="bibr" rid="c20">20</xref>) (<xref ref-type="bibr" rid="c21">21</xref>,<xref ref-type="bibr" rid="c22">22</xref>)which involves complex interactions between troponin I and troponin C (<xref ref-type="bibr" rid="c43">43</xref>,<xref ref-type="bibr" rid="c44">44</xref>). Levosimendan is a calcium sensitiser, which canonically also exerts action on troponin C that is implicated in several diseases, including hypertrophic cardiomyopathy (<xref ref-type="bibr" rid="c45">45</xref>). Both troponin C and I (as well troponin T) are part of the troponin complex, with troponin I interacting with troponin C to regulate calcium sensitivity and contractility.(<xref ref-type="bibr" rid="c45">45</xref>) The translation of these findings to physiology is not straightforward since the effects of these target TNNI3 polymorphisms on the contribution of troponin I to myocardial Ca sensing are not established. Consequently, this finding may indicate either impaired calcium sensing in the presence of these SNPs, in which case a calcium sensitiser (such as levosimendan) may be helpful. Alternatively, these SNPs may drive greater Ca myocardial Ca sensitivity, and the increased blood levels of troponin I and poor outcomes seen in their presence may be due to myocardial necrosis in the presence of excessive myocardial stress &#x2013; in which case Ca channel blockers might be indicated. In any event, our findings make a strong case for further exploration of this physiology and, potentially, clinical trials of promising interventions.(<xref ref-type="bibr" rid="c46">46</xref>)</p>
<p>MHC1A, also known as MICA, encodes a 62 kDa cell surface glycoprotein which is expressed on endothelial, dendritic, epithelial cells and fibroblasts. It is a target for cellular and humoral immune responses and becomes upregulated in response to stimuli of cellular stress like DNA damage and viral infection.(<xref ref-type="bibr" rid="c47">47</xref>) MHC1A binds to the natural killer group 2D (NKG2D) transmembrane protein activating natural killer cells, &#x03B3;&#x03B4; T cells and CD8<sup>&#x002B;</sup> &#x03B1;&#x03B2; T cells implicated in the antiviral response (<xref ref-type="bibr" rid="c48">48</xref>). Severe COVID-19 patients show high counts of NKG2C cells and low counts of NKG2D cells (<xref ref-type="bibr" rid="c49">49</xref>,<xref ref-type="bibr" rid="c50">50</xref>). Our findings suggest that a genetic propensity for higher blood MHC1A may protect against severe COVID-19, potentially through activating cytolytic cells (OR = 0.60, 95&#x0025; CI: 0.41-0.78).</p>
<p>The natural cytotoxicity triggering receptor 3 (NCR3, also known as NKp30) is expressed by NK cells as well as by some peripheral blood CD8&#x002B; and &#x03B3;&#x03B4; T cells and mediates NK cytotoxicity by facilitating the crosstalk between NK and dendritic cells.(<xref ref-type="bibr" rid="c51">51</xref>) NCR3 becomes upregulated in response to interferon &#x03B3; and bacterial infection, suggesting a role in inflammatory and infectious diseases.(<xref ref-type="bibr" rid="c52">52</xref>) A separate transcriptomic analysis showed that reduced NCR3 transcription is associated with more severe influenza(<xref ref-type="bibr" rid="c53">53</xref>) while NCR3 plays important roles in both immunity against viral infections and in the development of immune evasion by viruses.(<xref ref-type="bibr" rid="c54">54</xref>) Our findings suggest that a genetic predisposition for higher blood NCR3 may protect against severe COVID-19 (OR = 0.46, 95&#x0025; CI: 0.06-0.86).(<xref ref-type="bibr" rid="c55">55</xref>&#x2013;<xref ref-type="bibr" rid="c57">57</xref>) However, we note that this association is with the soluble form of NCR3 found in plasma, complicating the interpretation of the results.</p>
<p>A one SD increase in levels of C4a-C4b was associated with COVID-19 severity (OR = 1.76, 95&#x0025; CI 1.51-2.01). The C4a-C4b heterodimer is part of the complement cascade, which plays an important role in the host defense response against viral infections but has also been robustly associated with schizophrenia(<xref ref-type="bibr" rid="c58">58</xref>,<xref ref-type="bibr" rid="c59">59</xref>), with the associated C4 structural variants leading to possible altered neural C4A expression, excessive or inappropriate synaptic pruning(<xref ref-type="bibr" rid="c60">60</xref>,<xref ref-type="bibr" rid="c61">61</xref>). However, while a diagnosis of schizophrenia has been reported to be associated with a &#x003E;7-fold increased risk for infection and almost a 3-fold increase in risk of mortality for COVID-19(<xref ref-type="bibr" rid="c62">62</xref>,<xref ref-type="bibr" rid="c63">63</xref>), additional sensitivity analyses did not show any significant Mendelian randomization between the general genetics of schizophrenia(<xref ref-type="bibr" rid="c64">64</xref>) and severe COVID-19 (see Supplementary Table 6). Activation of the classical, lectin and alternative complement pathways is associated with severity of COVID-19,(<xref ref-type="bibr" rid="c65">65</xref>&#x2013;<xref ref-type="bibr" rid="c67">67</xref>) and microvascular injury and thrombosis in fatal cases.(<xref ref-type="bibr" rid="c67">67</xref>,<xref ref-type="bibr" rid="c68">68</xref>) Small non-randomised studies(<xref ref-type="bibr" rid="c69">69</xref>,<xref ref-type="bibr" rid="c70">70</xref>) have suggest the C5 inhibitor, eculizumab is a potential therapeutic for COVID-19. Finally in the MHC region, we also found evidence that HLA-DQA2 is causally associated with severe COVID-19 (OR = 2.29, 95&#x0025; CI 1.94-2.64). In contrast to other HLA class II molecules, HLA-DQA2 is less polymorphic with a more discrete expression profile.(<xref ref-type="bibr" rid="c71">71</xref>)<sup>,(<xref ref-type="bibr" rid="c72">72</xref>)</sup>.</p>
<p>Turning to non-MHC proteins, we find proteinase 3 (PRTN3; OR = 2.48, 95&#x0025; CI: 2.04-2.91) is causally associated with severe COVID-19. PRTN3 is a serine proteinase expressed in neutrophil granulocytes and a constituent of azurophil granules, that contain proteases and antibacterial proteins. PRTN3 is involved in neutrophil degranulation, highly overexpressed (29-fold) in naso-oropharyngeal samples of COVID-19 patients,(<xref ref-type="bibr" rid="c73">73</xref>) and associated with greater COVID-19 severity.(<xref ref-type="bibr" rid="c74">74</xref>) Neutrophil degranulation itself is dysregulated in COVID-19(<xref ref-type="bibr" rid="c75">75</xref>) while the myelopoiesis produces immature and dysfunctional neutrophils in severe COVID-19.(<xref ref-type="bibr" rid="c76">76</xref>) Given that PRTN3 is also implicated in immune dysregulation, sepsis and acute kidney injury,(<xref ref-type="bibr" rid="c77">77</xref>) this molecule may represent an interesting target to modulate immune responses against SARS-CoV-2.</p>
<p>The LDL receptor-related protein associated protein 1 (LRPAP1; OR = 1.73, 95&#x0025; CI: 1.49-1.97) is involved as an escort protein in trafficking members of the LDL receptor family through the endoplasmic reticulum and Golgi apparatus preventing premature binding of ligands with these receptors.(<xref ref-type="bibr" rid="c78">78</xref>) In COVID-19, LDL cholesterol below or equal to 69 mg/dl has been associated with poor clinical outcomes.(<xref ref-type="bibr" rid="c79">79</xref>) Regarding a potential involvement in the development of neurological and cardiovascular symptoms, genomic variants in LRPAP1 have been associated with late-onset Alzheimer&#x2019;s and Parkinson&#x2019;s disease while serum anti-LRPAP1 is commonly used as a biomarker for atherosclerotic diseases.(<xref ref-type="bibr" rid="c80">80</xref>&#x2013;<xref ref-type="bibr" rid="c82">82</xref>)</p>
<p>Our study has several limitations. Firstly, although we required confirmation of our findings by several Mendelian randomization methods, the <italic>p</italic>-value threshold for selecting genetic variants as instruments for our analyses was set at suggestive significance (<italic>p</italic> &#x003C; 5 &#x00D7; 10<sup>&#x2212;6</sup>) to allow enough to be identified for each protein, meaning that some of the genetic variants may not have true associations with protein levels. Secondly, some blood marker GWASs were excluded from our analyses due to unavailability, therefore, we may have missed associations with these markers. Thirdly, the severe COVID-19 GWAS used is of small sample size, reducing power to detect associations. However, it was a GWAS of the extreme phenotype of COVID-19 mortality or ventilator support, which may compensate for this.(<xref ref-type="bibr" rid="c83">83</xref>) Finally, our findings are limited to ancestral European populations due to data availability. Future endeavours should include participants from diverse ancestry groups.</p>
<p>Our results highlight the utility of applying large scale Mendelian randomization analyses to identify blood markers that may be causal for severe COVID-19. We demonstrate that TNNI3, PRTN3, HLADQA2, C4a-C4b and LRPAP1 may increase risk for severe COVID-19 while MHC1A and NCR3 may protect against severe COVID-19. These blood markers may play a role in the severity of COVID-19, indicating possible avenues to develop prognostic biomarkers and therapeutics for COVID-19.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material>
<label>Supplementary Materials</label>
<media xlink:href="supplements/253206_file02.docx" />
</supplementary-material>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>All data and software is publicly available via original sources.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>This study is supported by the National Institute for Health Research (NIHR) Mental Health Translational Research Collaboration (MH-TRC). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.</p>
</ack>
<sec id="s5">
<title>Funding</title>
<p>COVID-19 Clinical Neuroscience Study funded by the Medical Research Council (Grant Code: MR/V03605X/1).</p>
</sec>
<sec id="s6">
<title>Author contributions</title>
<p>ABP, VM and CH collected, processed and analysed the data. ABP, VM, CH and GB wrote the manuscript. DM, LT and BM helped write the manuscript and added expert knowledge. This work was carried out as part of the COVID Clinical Neuroscience Study consortium.</p>
</sec>
<sec id="s7">
<title>Competing interests</title>
<p>GB has received consultancy fees from Compass Pathways Ltd and Otsuka Ltd. There are no other conflicts to disclose.</p>
</sec>
<sec id="s8">
<title>Data availability</title>
<p>All data and software is publicly available via original sources.</p>
</sec><glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>C4A</term>
<def><p>complement C4A (Rodgers blood group)</p></def>
</def-item>
<def-item>
<term>C4B</term>
<def><p>complement C4B (Chido blood group)</p></def>
</def-item>
<def-item>
<term>CREB3L4</term>
<def><p>cAMP responsive element binding protein 3 like 4</p></def>
</def-item>
<def-item>
<term>COVID-19</term>
<def><p>coronavirus disease 2019</p></def>
</def-item>
<def-item>
<term>DEFB119</term>
<def><p>beta-defensin 119</p></def>
</def-item>
<def-item>
<term>GWAS</term>
<def><p>genome-wide association study</p></def>
</def-item>
<def-item>
<term>HLA-DQA2</term>
<def><p>major histocompatibility complex (MHC), class II, DQ alpha 2</p></def>
</def-item>
<def-item>
<term>LRPAP1</term>
<def><p>low-density lipoprotein (LDL) receptor-related protein associated protein 1</p></def>
</def-item>
<def-item>
<term>MICA</term>
<def><p>MHC class I polypeptide-related sequence A</p></def>
</def-item>
<def-item>
<term>NCR3</term>
<def><p>natural cytotoxicity triggering receptor 3</p></def>
</def-item>
<def-item>
<term>OR</term>
<def><p>odds ratio</p></def>
</def-item>
<def-item>
<term>PRTN3</term>
<def><p>proteinase 3</p></def>
</def-item>
<def-item>
<term>TNNI3</term>
<def><p>troponin I3, cardiac type</p></def>
</def-item>
<def-item>
<term>SARS-CoV-2</term>
<def><p>severe acute respiratory syndrome coronavirus 2</p></def>
</def-item>
<def-item>
<term>SE</term>
<def><p>standard error</p></def>
</def-item>
<def-item>
<term>SNP</term>
<def><p>single nucleotide polymorphism</p></def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Blanco-Melo</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Nilsson-Payant</surname>, <given-names>B. E.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>W.-C.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19</article-title>. <source>Cell</source>, <volume>181</volume>, <fpage>1036</fpage>&#x2013;<lpage>1045</lpage>.e9.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Garc&#x00ED;a</surname>, <given-names>L. F.</given-names></string-name> (<year>2020</year>) <article-title>Immune Response, Inflammation, and the Clinical Spectrum of COVID-19</article-title>. <source>Front. Immunol</source>., <volume>11</volume>, <fpage>1441</fpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Dong</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Du</surname>, <given-names>H.</given-names></string-name> and <string-name><surname>Gardner</surname>, <given-names>L.</given-names></string-name> (<year>2020</year>) <article-title>An interactive web-based dashboard to track COVID-19 in real time</article-title>. <source>Lancet Infect. Dis</source>., <volume>20</volume>, <fpage>533</fpage>&#x2013;<lpage>534</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="other"><string-name><surname>Berlin</surname>, <given-names>D. A.</given-names></string-name>, <string-name><surname>Gulick</surname>, <given-names>R. M.</given-names></string-name> and <string-name><surname>Martinez</surname>, <given-names>F. J.</given-names></string-name> (<year>2020</year>) <article-title>Severe Covid-19</article-title>. <source>N. Engl. J. Med., 383, 2451&#x2013;2460</source>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Kadkhoda</surname>, <given-names>K.</given-names></string-name> (<year>2020</year>) <article-title>COVID-19: an Immunopathological View</article-title>. <source>mSphere</source>, <volume>5</volume>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Ovsyannikova</surname>, <given-names>I. G.</given-names></string-name>, <string-name><surname>Haralambieva</surname>, <given-names>I. H.</given-names></string-name>, <string-name><surname>Crooke</surname>, <given-names>S. N.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity</article-title>. <source>Immunol. Rev</source>., <volume>296</volume>, <fpage>205</fpage>&#x2013;<lpage>219</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Fajgenbaum</surname>, <given-names>D. C.</given-names></string-name> and <string-name><surname>June</surname>, <given-names>C. H.</given-names></string-name> (<year>2020</year>) <article-title>Cytokine Storm</article-title>. <source>N. Engl. J. Med</source>., <volume>383</volume>, <fpage>2255</fpage>&#x2013;<lpage>2273</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="other"><string-name><surname>Sarma</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Christenson</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Mick</surname>, <given-names>E.</given-names></string-name>, <etal>et al.</etal> (<year>2021</year>) <article-title>COVID-19 ARDS is characterized by a dysregulated host response that differs from cytokine storm and is modified by dexamethasone</article-title>. <source>Res Sq</source>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="other"><string-name><surname>Palmos</surname>, <given-names>A. B.</given-names></string-name>, <string-name><surname>Chung</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Frissa</surname>, <given-names>S.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Reconsidering the reasons for heightened inflammation in major depressive disorder</article-title>. <source>J. Affect. Disord</source>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Palmos</surname>, <given-names>A. B.</given-names></string-name>, <string-name><surname>Watson</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Hughes</surname>, <given-names>T.</given-names></string-name>, <etal>et al.</etal> (<year>2019</year>) <article-title>Associations between childhood maltreatment and inflammatory markers</article-title>. <source>BJPsych Open</source>, <volume>5</volume>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Monteiro</surname>, <given-names>A. C.</given-names></string-name>, <string-name><surname>Suri</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Emeruwa</surname>, <given-names>I. O.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Obesity and smoking as risk factors for invasive mechanical ventilation in COVID-19: A retrospective, observational cohort study</article-title>. <source>PLoS One</source>, <volume>15</volume>, <fpage>e0238552</fpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Sliz</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Kalaoja</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ahola-Olli</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal> (<year>2019</year>) <article-title>Genome-wide association study identifies seven novel loci associating with circulating cytokines and cell adhesion molecules in Finns</article-title>. <source>J. Med. Genet</source>., <volume>56</volume>, <fpage>607</fpage>&#x2013;<lpage>616</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Ahola-Olli</surname>, <given-names>A. V.</given-names></string-name>, <string-name><surname>W&#x00FC;rtz</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Havulinna</surname>, <given-names>A. S.</given-names></string-name>, <etal>et al.</etal> (<year>2017</year>) <article-title>Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors</article-title>. <source>Am. J. Hum. Genet</source>., <volume>100</volume>, <fpage>40</fpage>&#x2013;<lpage>50</lpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>H&#x00F6;glund</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Rafati</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Rask-Andersen</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal> (<year>2019</year>) <article-title>Improved power and precision with whole genome sequencing data in genome-wide association studies of inflammatory biomarkers</article-title>. <source>Sci. Rep</source>., <volume>9</volume>, <fpage>16844</fpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><collab>COVID-19 Host Genetics Initiative</collab> (<year>2020</year>) <article-title>The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic</article-title>. <source>Eur. J. Hum. Genet</source>., <volume>28</volume>, <fpage>715</fpage>&#x2013;<lpage>718</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Burgess</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Foley</surname>, <given-names>C. N.</given-names></string-name>, <string-name><surname>Allara</surname>, <given-names>E.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>A robust and efficient method for Mendelian randomization with hundreds of genetic variants</article-title>. <source>Nat. Commun</source>., <volume>11</volume>, <fpage>376</fpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Sumitran-Holgersson</surname>, <given-names>S.</given-names></string-name> (<year>2008</year>) <article-title>Beyond ABO and human histocompatibility antigen: other histocompatibility antigens with a role in transplantation</article-title>. <source>Curr. Opin. Organ Transplant</source>., <volume>13</volume>, <fpage>425</fpage>&#x2013;<lpage>429</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Howell</surname>, <given-names>W. M.</given-names></string-name>, <string-name><surname>Carter</surname>, <given-names>V.</given-names></string-name> and <string-name><surname>Clark</surname>, <given-names>B.</given-names></string-name> (<year>2010</year>) <article-title>The HLA system: immunobiology, HLA typing, antibody screening and crossmatching techniques</article-title>. <source>J. Clin. Pathol</source>., <volume>63</volume>, <fpage>387</fpage>&#x2013;<lpage>390</lpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Klein</surname>, <given-names>J.</given-names></string-name> and <string-name><surname>Sato</surname>, <given-names>A.</given-names></string-name> (<year>2000</year>) <article-title>The HLA system. First of two parts</article-title>. <source>N. Engl. J. Med</source>., <volume>343</volume>, <fpage>702</fpage>&#x2013;<lpage>709</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Ghoussaini</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Mountjoy</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Carmona</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal> (<year>2021</year>) <article-title>Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics</article-title>. <source>Nucleic Acids Res</source>., <volume>49</volume>, <fpage>D1311</fpage>&#x2013;<lpage>D1320</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Kachooei</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Cordina</surname>, <given-names>N. M.</given-names></string-name>, <string-name><surname>Potluri</surname>, <given-names>P. R.</given-names></string-name>, <etal>et al.</etal> (<year>2021</year>) <article-title>Phosphorylation of Troponin I finely controls the positioning of Troponin for the optimal regulation of cardiac muscle contraction</article-title>. <source>J. Mol. Cell. Cardiol</source>., <volume>150</volume>, <fpage>44</fpage>&#x2013;<lpage>53</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Marston</surname>, <given-names>S.</given-names></string-name> and <string-name><surname>Zamora</surname>, <given-names>J. E.</given-names></string-name> (<year>2020</year>) <article-title>Troponin structure and function: a view of recent progress</article-title>. <source>J. Muscle Res. Cell Motil</source>., <volume>41</volume>, <fpage>71</fpage>&#x2013;<lpage>89</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="other"><string-name><surname>McGowan</surname>, <given-names>L. M.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>G. D.</given-names></string-name>, <string-name><surname>Gaunt</surname>, <given-names>T. R.</given-names></string-name>, <etal>et al.</etal> <article-title>Integrating Mendelian randomization and multiple-trait colocalization to uncover cell-specific inflammatory drivers of autoimmune and atopic disease</article-title>. <source>Integrating Mendelian randomization and multiple-trait colocalization to uncover cell-specific inflammatory drivers of autoimmune and atopic disease</source>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="other"><string-name><surname>Georgakis</surname>, <given-names>M. K.</given-names></string-name>, <string-name><surname>Gill</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Rannikm&#x00E4;e</surname>, <given-names>K.</given-names></string-name>, <etal>et al.</etal> (<year>2019</year>) <article-title>Genetically Determined Levels of Circulating Cytokines and Risk of Stroke. Genetically Determined Levels of Circulating Cytokines and Risk of Stroke</article-title>. <source>Circulation (2019), 139, 256&#x2013;268</source>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Reynolds</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Cecconi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Collinson</surname>, <given-names>P.</given-names></string-name>, <etal>et al.</etal> (<year>2012</year>) <article-title>Raised serum cardiac troponin I concentrations predict hospital mortality in intensive care unit patients</article-title>. <source>Br. J. Anaesth</source>., <volume>109</volume>, <fpage>219</fpage>&#x2013;<lpage>224</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Pantou</surname>, <given-names>M. P.</given-names></string-name>, <string-name><surname>Gourzi</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Gkouziouta</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal> (<year>2019</year>) <article-title>A case report of recessive restrictive cardiomyopathy caused by a novel mutation in cardiac troponin I (TNNI3)</article-title>. <source>BMC Med. Genet</source>., <volume>20</volume>, <fpage>61</fpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Ruan</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>W.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China</article-title>. <source>Intensive Care Med</source>., <volume>46</volume>, <fpage>846</fpage>&#x2013;<lpage>848</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Shi</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Qin</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Shen</surname>, <given-names>B.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China</article-title>. <source>JAMA Cardiol</source>, <volume>5</volume>, <fpage>802</fpage>&#x2013;<lpage>810</lpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Huang</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source>Lancet</source>, <volume>395</volume>, <fpage>497</fpage>&#x2013;<lpage>506</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Du</surname>, <given-names>R.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title>. <source>Lancet</source>, <volume>395</volume>, <fpage>1054</fpage>&#x2013;<lpage>1062</lpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Yang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>J.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</article-title>. <source>Lancet Respir Med</source>, <volume>8</volume>, <fpage>475</fpage>&#x2013;<lpage>481</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Guo</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Fan</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)</article-title>. <source>JAMA Cardiol</source>, <volume>5</volume>, <fpage>811</fpage>&#x2013;<lpage>818</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Hu</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Hu</surname>, <given-names>C.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus&#x2013;Infected Pneumonia in Wuhan, China</article-title>. <source>JAMA</source>, <volume>323</volume>, <fpage>1061</fpage>&#x2013;<lpage>1069</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>H.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study</article-title>. <source>BMJ</source>, <volume>368</volume>, <fpage>m1091</fpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Nie</surname>, <given-names>S.-F.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Xie</surname>, <given-names>T.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Cardiac Troponin I Is an Independent Predictor for Mortality in Hospitalized Patients With COVID-19</article-title>. <source>Circulation</source>, <volume>142</volume>, <fpage>608</fpage>&#x2013;<lpage>610</lpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Lombardi</surname>, <given-names>C. M.</given-names></string-name>, <string-name><surname>Carubelli</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Iorio</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study</article-title>. <source>JAMA Cardiol</source>, <volume>5</volume>, <fpage>1274</fpage>&#x2013;<lpage>1280</lpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Knight</surname>, <given-names>D. S.</given-names></string-name>, <string-name><surname>Kotecha</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Razvi</surname>, <given-names>Y.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>COVID-19: Myocardial Injury in Survivors</article-title>. <source>Circulation</source>, <volume>142</volume>, <fpage>1120</fpage>&#x2013;<lpage>1122</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Doyen</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Moceri</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Ducreux</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes</article-title>. <source>Lancet</source>, <volume>395</volume>, <fpage>1516</fpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Tersalvi</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Vicenzi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Calabretta</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms</article-title>. <source>J. Card. Fail</source>., <volume>26</volume>, <fpage>470</fpage>&#x2013;<lpage>475</lpage>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Majure</surname>, <given-names>D. T.</given-names></string-name>, <string-name><surname>Gruberg</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Saba</surname>, <given-names>S. G.</given-names></string-name>, <etal>et al.</etal> (<year>2021</year>) <article-title>Usefulness of Elevated Troponin to Predict Death in Patients With COVID-19 and Myocardial Injury</article-title>. <source>Am. J. Cardiol</source>., <volume>138</volume>, <fpage>100</fpage>&#x2013;<lpage>106</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Bos</surname>, <given-names>J. M.</given-names></string-name>, <string-name><surname>Hebl Virginia</surname> <given-names>B</given-names></string-name>s, <string-name><surname>Oberg</surname>, <given-names>A.L.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2eMediated COVID-19</article-title>. <source>Mayo Clinic Proceedings; Rochester</source>, <volume>95</volume>, <fpage>1354</fpage>&#x2013;<lpage>1368</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Ni</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19</article-title>. <source>Crit. Care</source>, <volume>24</volume>, <fpage>422</fpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="other"><string-name><surname>Genchev</surname>, <given-names>G. Z.</given-names></string-name>, <string-name><surname>Kobayashi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kobayashi</surname>, <given-names>T.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Molecular dynamics provides new insights into the mechanism of calcium signal transduction and inter-domain interactions in cardiac troponin</article-title>. <source>FEBS Open Bio</source>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Marston</surname>, <given-names>S. B.</given-names></string-name> and <string-name><surname>Redwood</surname>, <given-names>C. S.</given-names></string-name> (<year>2003</year>) <article-title>Modulation of thin filament activation by breakdown or isoform switching of thin filament proteins: physiological and pathological implications</article-title>. <source>Circ. Res</source>., <volume>93</volume>, <fpage>1170</fpage>&#x2013;<lpage>1178</lpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Robertson</surname>, <given-names>I. M.</given-names></string-name>, <string-name><surname>Baryshnikova</surname>, <given-names>O. K.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>M. X.</given-names></string-name>, <etal>et al.</etal> (<year>2008</year>) <article-title>Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex</article-title>. <source>Biochemistry</source>, <volume>47</volume>, <fpage>7485</fpage>&#x2013;<lpage>7495</lpage>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Akhmerov</surname>, <given-names>A.</given-names></string-name> and <string-name><surname>Marb&#x00E1;n</surname>, <given-names>E.</given-names></string-name> (<year>2020</year>) <article-title>COVID-19 and the Heart</article-title>. <source>Circ. Res</source>., <volume>126</volume>, <fpage>1443</fpage>&#x2013;<lpage>1455</lpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="other"><string-name><surname>Ahmed</surname>, <given-names>Z.</given-names></string-name> and <string-name><surname>Askar</surname>, <given-names>M.</given-names></string-name> (<year>2017</year>) <article-title>MICA (MHC class I polypeptide-related sequence A)</article-title>. <source>Atlas Genet. Cytogenet. Oncol. Haematol</source>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>, <given-names>J. L.-Y.</given-names></string-name>, <string-name><surname>Chang</surname>, <given-names>C.-C.</given-names></string-name>, <string-name><surname>Huang</surname>, <given-names>Y.-S.</given-names></string-name>, <etal>et al.</etal> (<year>2018</year>) <article-title>Persistently elevated soluble MHC class I polypeptide-related sequence A and transforming growth factor-&#x03B2;1 levels are poor prognostic factors in head and neck squamous cell carcinoma after definitive chemoradiotherapy</article-title>. <source>PLoS One</source>, <volume>13</volume>, <fpage>e0202224</fpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="other"><string-name><surname>Maucourant</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Filipovic</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Ponzetta</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Natural killer cell immunotypes related to COVID-19 disease severity</article-title>. <source>Sci Immunol, 5</source>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="other"><string-name><surname>Maucourant</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Filipovic</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Ponzetta</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Natural killer cell activation related to clinical outcome of COVID-19</article-title>. <source>medRxiv</source>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Mantovani</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Oliviero</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Lombardi</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal> (<year>2019</year>) <article-title>Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinoma: Hepatology</article-title>. <source>Hepatology</source>, <volume>69</volume>, <fpage>1165</fpage>&#x2013;<lpage>1179</lpage>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Mulcahy</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>O&#x2019;Rourke</surname>, <given-names>K. P.</given-names></string-name>, <string-name><surname>Adams</surname>, <given-names>C.</given-names></string-name>, <etal>et al.</etal> (<year>2006</year>) <article-title>LST1 and NCR3 expression in autoimmune inflammation and in response to IFN-gamma</article-title>, <source>LPS and microbial infection. Immunogenetics</source>, <volume>57</volume>, <fpage>893</fpage>&#x2013;<lpage>903</lpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Hoang</surname>, <given-names>L. T.</given-names></string-name>, <string-name><surname>Tolfvenstam</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Ooi</surname>, <given-names>E. E.</given-names></string-name>, <etal>et al.</etal> (<year>2014</year>) <article-title>Patient-based transcriptome-wide analysis identify interferon and ubiquination pathways as potential predictors of influenza A disease severity</article-title>. <source>PLoS One</source>, <volume>9</volume>, <fpage>e111640</fpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Hammer</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>R&#x00FC;ckert</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Borst</surname>, <given-names>E. M.</given-names></string-name>, <etal>et al.</etal> (<year>2018</year>) <article-title>Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells</article-title>. <source>Nat. Immunol</source>., <volume>19</volume>, <fpage>453</fpage>&#x2013;<lpage>463</lpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Jarahian</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Fiedler</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Cohnen</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal> (<year>2011</year>) <article-title>Modulation of NKp30- and NKp46-Mediated Natural Killer Cell Responses by Poxviral Hemagglutinin. Modulation of NKp30- and NKp46-Mediated Natural Killer Cell Responses by Poxviral Hemagglutinin</article-title>. <source>PLoS Pathogens (2011)</source>, <volume>7</volume>, <fpage>e1002195</fpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Semeraro</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Rusakiewicz</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Minard-Colin</surname>, <given-names>V.</given-names></string-name>, <etal>et al.</etal> (<year>2015</year>) <article-title>Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients</article-title>. <source>Sci. Transl. Med</source>., <volume>7</volume>, <fpage>283ra55</fpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Han</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Mao</surname>, <given-names>F.-Y.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>Y.-L.</given-names></string-name>, <etal>et al.</etal> (<year>2018</year>) <article-title>Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer</article-title>. <source>J Immunol Res</source>, <volume>2018</volume>, <fpage>6248590</fpage>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Sekar</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Bialas</surname>, <given-names>A. R.</given-names></string-name>, <string-name><surname>de Rivera</surname>, <given-names>H.</given-names></string-name>, <etal>et al.</etal> (<year>2016</year>) <article-title>Schizophrenia risk from complex variation of complement component 4</article-title>. <source>Nature</source>, <volume>530</volume>, <fpage>177</fpage>&#x2013;<lpage>183</lpage>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Liao</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal> (<year>2017</year>) <article-title>Corrigendum: Association between C4, C4A, and C4B copy number variations and susceptibility to autoimmune diseases: a meta-analysis</article-title>. <source>Sci. Rep</source>., <volume>7</volume>, <fpage>46785</fpage>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Woo</surname>, <given-names>J. J.</given-names></string-name>, <string-name><surname>Pouget</surname>, <given-names>J. G.</given-names></string-name>, <string-name><surname>Zai</surname>, <given-names>C. C.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>The complement system in schizophrenia: where are we now and what&#x2019;s next?</article-title> <source>Mol. Psychiatry</source>, <volume>25</volume>, <fpage>114</fpage>&#x2013;<lpage>130</lpage>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>Nimgaonkar</surname>, <given-names>V. L.</given-names></string-name>, <string-name><surname>Prasad</surname>, <given-names>K. M.</given-names></string-name>, <string-name><surname>Chowdari</surname>, <given-names>K. V.</given-names></string-name>, <etal>et al.</etal> (<year>2017</year>) <article-title>The complement system: a gateway to gene-environment interactions in schizophrenia pathogenesis</article-title>. <source>Mol. Psychiatry</source>, <volume>22</volume>, <fpage>1554</fpage>&#x2013;<lpage>1561</lpage>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>R.</given-names></string-name> and <string-name><surname>Volkow</surname>, <given-names>N. D.</given-names></string-name> (<year>2021</year>) <article-title>Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States</article-title>. <source>World Psychiatry</source>, <volume>20</volume>, <fpage>124</fpage>&#x2013;<lpage>130</lpage>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="other"><string-name><surname>Nemani</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Olfson</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal> (<year>2021</year>) <article-title>Association of Psychiatric Disorders With Mortality Among Patients With COVID-19</article-title>. <source>JAMA Psychiatry</source>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Pardi&#x00F1;as</surname>, <given-names>A. F.</given-names></string-name>, <string-name><surname>Holmans</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Pocklington</surname>, <given-names>A. J.</given-names></string-name>, <etal>et al.</etal> (<year>2018</year>) <article-title>Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection</article-title>. <source>Nat. Genet</source>., <volume>50</volume>, <fpage>381</fpage>&#x2013;<lpage>389</lpage>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="other"><string-name><surname>Holter</surname>, <given-names>J. C.</given-names></string-name>, <string-name><surname>Pischke</surname>, <given-names>S. E.</given-names></string-name>, <string-name><surname>de Boer</surname>, <given-names>E.</given-names></string-name>, <etal>et al.</etal> <article-title>Systemic Complement Activation Is Associated with Respiratory Failure in COVID-19 Hospitalized Patients: A Prospective Cohort Study. Systemic Complement Activation Is Associated with Respiratory Failure in COVID-19 Hospitalized Patients: A Prospective Cohort Study</article-title>. <source>SSRN Electronic Journal</source>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="other"><string-name><surname>Malaquias</surname>, <given-names>M. A. S.</given-names></string-name>, <string-name><surname>Gadotti</surname>, <given-names>A. C.</given-names></string-name>, <string-name><surname>Motta-Junior</surname>, <given-names>J. da S.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>The role of the lectin pathway of the complement system in SARS-CoV-2 lung injury</article-title>. <source>Transl. Res</source>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="other"><string-name><surname>Macor</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Durigutto</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Mangogna</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal> (<year>2021</year>) <article-title>Multi-organ complement deposition in COVID-19 patients</article-title>. <source>medRxiv</source>.</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><string-name><surname>Magro</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Mulvey</surname>, <given-names>J. J.</given-names></string-name>, <string-name><surname>Berlin</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases</article-title>. <source>Transl. Res</source>., <volume>220</volume>, <fpage>1</fpage>&#x2013;<lpage>13</lpage>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><string-name><surname>Annane</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Heming</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Grimaldi-Bensouda</surname>, <given-names>L.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study</article-title>. <source>EClinicalMedicine</source>, <volume>28</volume>, <fpage>100590</fpage>.</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><string-name><surname>Laurence</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Mulvey</surname>, <given-names>J. J.</given-names></string-name>, <string-name><surname>Seshadri</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19</article-title>. <source>Clin. Immunol</source>., <volume>219</volume>, <fpage>108555</fpage>.</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><string-name><surname>Yu</surname>, <given-names>L. P.</given-names></string-name> and <string-name><surname>Sheehy</surname>, <given-names>M. J.</given-names></string-name> (<year>1991</year>) <article-title>The cryptic HLA-DQA2 (&#x201C;DX alpha&#x201D;) gene is expressed in human B cell lines</article-title>. <source>J. Immunol</source>., <volume>147</volume>, <fpage>4393</fpage>&#x2013;<lpage>4397</lpage>.</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><string-name><surname>Lenormand</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Bausinger</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Gross</surname>, <given-names>F.</given-names></string-name>, <etal>et al.</etal> (<year>2012</year>) <article-title>HLA-DQA2 and HLA-DQB2 genes are specifically expressed in human Langerhans cells and encode a new HLA class II molecule</article-title>. <source>J. Immunol</source>., <volume>188</volume>, <fpage>3903</fpage>&#x2013;<lpage>3911</lpage>.</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><string-name><surname>Akgun</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Tuzuner</surname>, <given-names>M. B.</given-names></string-name>, <string-name><surname>Sahin</surname>, <given-names>B.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Proteins associated with neutrophil degranulation are upregulated in nasopharyngeal swabs from SARS-CoV-2 patients</article-title>. <source>PLoS One</source>, <volume>15</volume>, <fpage>e0240012</fpage>.</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="other"><string-name><surname>Gisby</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Clarke</surname>, <given-names>C. L.</given-names></string-name>, <string-name><surname>Medjeral-Thomas</surname>, <given-names>N.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Longitudinal proteomic profiling of high-risk patients with COVID-19 reveals markers of severity and predictors of fatal disease. Longitudinal proteomic profiling of high-risk patients with COVID-19 reveals markers of severity and predictors of fatal disease</article-title>. <source>bioRxiv (2020)</source>.</mixed-citation></ref>
<ref id="c75"><label>75.</label><mixed-citation publication-type="journal"><string-name><surname>Overmyer</surname>, <given-names>K. A.</given-names></string-name>, <string-name><surname>Shishkova</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Miller</surname>, <given-names>I. J.</given-names></string-name>, <etal>et al.</etal> (<year>2021</year>) <article-title>Large-Scale Multi-omic Analysis of COVID-19 Severity</article-title>. <source>Cell Syst</source>, <volume>12</volume>, <fpage>23</fpage>&#x2013;<lpage>40</lpage>.e7.</mixed-citation></ref>
<ref id="c76"><label>76.</label><mixed-citation publication-type="journal"><string-name><surname>Schulte-Schrepping</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Reusch</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Paclik</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment</article-title>. <source>Cell</source>, <volume>182</volume>, <fpage>1419</fpage>&#x2013;<lpage>1440</lpage>.e23.</mixed-citation></ref>
<ref id="c77"><label>77.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>R.</given-names></string-name>, <etal>et al.</etal> (<year>2019</year>) <article-title>LTF, PRTN3, and MNDA in Synovial Fluid as Promising Biomarkers for Periprosthetic Joint Infection: Identification by Quadrupole Orbital-Trap Mass Spectrometry</article-title>. <source>J. Bone Joint Surg. Am</source>., <volume>101</volume>, <fpage>2226</fpage>&#x2013;<lpage>2234</lpage>.</mixed-citation></ref>
<ref id="c78"><label>78.</label><mixed-citation publication-type="journal"><string-name><surname>Van Leuven</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Thiry</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Stas</surname>, <given-names>L.</given-names></string-name>, <etal>et al.</etal> (<year>1998</year>) <article-title>Analysis of the human LRPAP1 gene coding for the lipoprotein receptor-associated protein: identification of 22 polymorphisms and one mutation</article-title>. <source>Genomics</source>, <volume>52</volume>, <fpage>145</fpage>&#x2013;<lpage>151</lpage>.</mixed-citation></ref>
<ref id="c79"><label>79.</label><mixed-citation publication-type="other"><string-name><surname>Aparisi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Iglesias-Echeverria</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Ybarra-Falcon</surname>, <given-names>C.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19</article-title>. <source>medRxiv</source>.</mixed-citation></ref>
<ref id="c80"><label>80.</label><mixed-citation publication-type="journal"><string-name><surname>Sumazaki</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Shimada</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ito</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases</article-title>. <source>Cancer Sci</source>., <volume>111</volume>, <fpage>4453</fpage>&#x2013;<lpage>4464</lpage>.</mixed-citation></ref>
<ref id="c81"><label>81.</label><mixed-citation publication-type="journal"><string-name><surname>Singh</surname>, <given-names>N. K.</given-names></string-name>, <string-name><surname>Banerjee</surname>, <given-names>B. D.</given-names></string-name>, <string-name><surname>Bala</surname>, <given-names>K.</given-names></string-name>, <etal>et al.</etal> (<year>2014</year>) <article-title>APOE and LRPAP1 gene polymorphism and risk of Parkinson&#x2019;s disease</article-title>. <source>Neurol. Sci</source>., <volume>35</volume>, <fpage>1075</fpage>&#x2013;<lpage>1081</lpage>.</mixed-citation></ref>
<ref id="c82"><label>82.</label><mixed-citation publication-type="other"><string-name><surname>S&#x00E1;nchez</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Alvarez</surname>, <given-names>V.</given-names></string-name> and <string-name><surname>Gonz&#x00E1;lez</surname>, <given-names>P.</given-names></string-name> (<year>2001</year>) <article-title>Variation in the LRP-associated protein gene (LRPAP1) is associated with late-onset Alzheimer disease</article-title>. <source>American journal of</source>.</mixed-citation></ref>
<ref id="c83"><label>83.</label><mixed-citation publication-type="journal"><string-name><surname>Zabaneh</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Krapohl</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Gaspar</surname>, <given-names>H. A.</given-names></string-name>, <etal>et al.</etal> (<year>2018</year>) <article-title>A genome-wide association study for extremely high intelligence</article-title>. <source>Mol. Psychiatry</source>, <volume>23</volume>, <fpage>1226</fpage>&#x2013;<lpage>1232</lpage>.</mixed-citation></ref>
<ref id="c84"><label>84.</label><mixed-citation publication-type="journal"><string-name><surname>Sun</surname>, <given-names>B. B.</given-names></string-name>, <string-name><surname>Maranville</surname>, <given-names>J. C.</given-names></string-name>, <string-name><surname>Peters</surname>, <given-names>J. E.</given-names></string-name>, <etal>et al.</etal> (<year>2018</year>) <article-title>Genomic atlas of the human plasma proteome</article-title>. <source>Nature</source>, <volume>558</volume>, <fpage>73</fpage>&#x2013;<lpage>79</lpage>.</mixed-citation></ref>
<ref id="c85"><label>85.</label><mixed-citation publication-type="journal"><string-name><surname>Suhre</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Arnold</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Bhagwat</surname>, <given-names>A. M.</given-names></string-name>, <etal>et al.</etal> (<year>2017</year>) <article-title>Connecting genetic risk to disease end points through the human blood plasma proteome</article-title>. <source>Nat. Commun</source>., <volume>8</volume>, <fpage>14357</fpage>.</mixed-citation></ref>
<ref id="c86"><label>86.</label><mixed-citation publication-type="journal"><string-name><surname>Wood</surname>, <given-names>A. R.</given-names></string-name>, <string-name><surname>Perry</surname>, <given-names>J. R. B.</given-names></string-name>, <string-name><surname>Tanaka</surname>, <given-names>T.</given-names></string-name>, <etal>et al.</etal> (<year>2013</year>) <article-title>Imputation of variants from the 1000 Genomes Project modestly improves known associations and can identify low-frequency variant-phenotype associations undetected by HapMap based imputation</article-title>. <source>PLoS One</source>, <volume>8</volume>, <fpage>e64343</fpage>.</mixed-citation></ref>
<ref id="c87"><label>87.</label><mixed-citation publication-type="journal"><string-name><surname>Folkersen</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Fauman</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Sabater-Lleal</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal> (<year>2017</year>) <article-title>Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease</article-title>. <source>PLoS Genet</source>., <volume>13</volume>, <fpage>e1006706</fpage>.</mixed-citation></ref>
<ref id="c88"><label>88.</label><mixed-citation publication-type="journal"><string-name><surname>Folkersen</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Gustafsson</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Q.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals</article-title>. <source>Nat Metab</source>, <volume>2</volume>, <fpage>1135</fpage>&#x2013;<lpage>1148</lpage>.</mixed-citation></ref>
<ref id="c89"><label>89.</label><mixed-citation publication-type="journal"><string-name><surname>Bretherick</surname>, <given-names>A. D.</given-names></string-name>, <string-name><surname>Canela-Xandri</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Joshi</surname>, <given-names>P. K.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Linking protein to phenotype with Mendelian Randomization detects 38 proteins with causal roles in human diseases and traits</article-title>. <source>PLoS Genet</source>., <volume>16</volume>, <fpage>e1008785</fpage>.</mixed-citation></ref>
<ref id="c90"><label>90.</label><mixed-citation publication-type="journal"><string-name><surname>MacArthur</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Bowler</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Cerezo</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal> (<year>2017</year>) <article-title>The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog)</article-title>. <source>Nucleic Acids Res</source>., <volume>45</volume>, <fpage>D896</fpage>&#x2013;<lpage>D901</lpage>.</mixed-citation></ref>
<ref id="c91"><label>91.</label><mixed-citation publication-type="journal"><collab>1000 Genomes Project Consortium, The 1000 Genomes Project</collab>, <string-name><surname>Auton</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Brooks</surname>, <given-names>L. D.</given-names></string-name>, <etal>et al.</etal> (<year>2015</year>) <article-title>A global reference for human genetic variation</article-title>. <source>Nature</source>, <volume>526</volume>, <fpage>68</fpage>&#x2013;<lpage>74</lpage>.</mixed-citation></ref>
<ref id="c92"><label>92.</label><mixed-citation publication-type="journal"><string-name><surname>Zhu</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Zheng</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>F.</given-names></string-name>, <etal>et al.</etal> (<year>2018</year>) <article-title>Causal associations between risk factors and common diseases inferred from GWAS summary data</article-title>. <source>Nat. Commun</source>., <volume>9</volume>, <fpage>224</fpage>.</mixed-citation></ref>
<ref id="c93"><label>93.</label><mixed-citation publication-type="journal"><string-name><surname>Benjamini</surname>, <given-names>Y.</given-names></string-name> and <string-name><surname>Hochberg</surname>, <given-names>Y.</given-names></string-name> (<year>1995</year>) <article-title>Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing</article-title>. <source>J. R. Stat. Soc. Series B Stat. Methodol</source>., <volume>57</volume>, <fpage>289</fpage>&#x2013;<lpage>300</lpage>.</mixed-citation></ref>
<ref id="c94"><label>94.</label><mixed-citation publication-type="journal"><string-name><surname>Hemani</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Bowden</surname>, <given-names>J.</given-names></string-name> and <string-name><surname>Davey Smith</surname>, <given-names>G.</given-names></string-name> (<year>2018</year>) <article-title>Evaluating the potential role of pleiotropy in Mendelian randomization studies</article-title>. <source>Hum. Mol. Genet</source>., <volume>27</volume>, <fpage>R195</fpage>&#x2013;<lpage>R208</lpage>.</mixed-citation></ref>
<ref id="c95"><label>95.</label><mixed-citation publication-type="journal"><string-name><surname>Bowden</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Del Greco</surname> <given-names>MF.</given-names></string-name>, <string-name><surname>Minelli</surname>, <given-names>C.</given-names></string-name>, <etal>et al.</etal> (<year>2017</year>) <article-title>A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization</article-title>. <source>Stat. Med</source>., <volume>36</volume>, <fpage>1783</fpage>&#x2013;<lpage>1802</lpage>.</mixed-citation></ref>
<ref id="c96"><label>96.</label><mixed-citation publication-type="journal"><string-name><surname>Teumer</surname>, <given-names>A.</given-names></string-name> (<year>2018</year>) <article-title>Common Methods for Performing Mendelian Randomization</article-title>. <source>Front Cardiovasc Med</source>, <volume>5</volume>, <fpage>51</fpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>